Medicine and Dentistry
Patient
100%
Man
89%
Therapeutic Procedure
85%
Symptom
61%
Prostate Cancer
59%
Adverse Event
57%
Prostate Hypertrophy
49%
Lower Urinary Tract Symptom
47%
Systematic Review
44%
Combination Therapy
41%
Prostatectomy
37%
Randomized Controlled Trial
36%
Transurethral Resection
34%
Prostate Specific Antigen
32%
Quality of Life
31%
Follow up
30%
Surgery
25%
International Prostate Symptom Score
23%
Arterial Embolization
23%
Inpatient
22%
Meta-Analysis
21%
Robot-Assisted Prostatectomy
20%
Alpha Adrenergic Receptor Blocking Agent
20%
Health
19%
Prostate
16%
Age
15%
Analysis
15%
Transrectal Ultrasonography
15%
Stone
14%
Bladder
14%
Prostatitis
13%
Prognostic Factor
13%
Clear Cell Renal Cell Carcinoma
13%
Chemotherapy
13%
Desmopressin
13%
Sedation
13%
Malignant Neoplasm
13%
Child
13%
Complication
12%
Language
12%
Water
12%
Serum
12%
Diseases
12%
Incidence
11%
Urinary System
10%
Diagnosis
10%
Male
10%
Urolithiasis
10%
Neoplasm
9%
Random Effects Model
9%
Assessment
9%
Chronic Pelvic Pain Syndrome
9%
Health Care Cost
9%
Pelvis
9%
Silodosin
9%
Monotherapy
9%
Retreatment
9%
Cell Therapy
8%
Development
8%
Transitional Cell Carcinoma
8%
Erectile Dysfunction
8%
Experience
8%
Partial Nephrectomy
8%
Naftopidil
8%
Minimally Invasive Procedure
7%
Continence
7%
Screening
7%
Parasympatholytic
7%
Computer Assisted Tomography
7%
Tissues
7%
Overall Survival
7%
Cancer Risk Factor
7%
Digital Rectal Examination
7%
Recurrent Disease
7%
Nocturia
6%
Single Drug Dose
6%
Specimen
6%
Extracorporeal Shockwave Therapy
6%
Nephroureterectomy
6%
Lithotripsy
6%
Shock (Circulatory)
6%
Evaluation Study
6%
Anxiety
6%
Gleason Score
5%
Metabolic Syndrome
5%
Platelet-Activating Factor
5%
Enucleation
5%
Lesion
5%
Obstruction
5%
In Vitro
5%
Steroid 5alpha Reductase Inhibitor
5%
Tamsulosin
5%
Odds Ratio
5%
Pembrolizumab
5%
Postoperative Complication
5%
Obstetric Delivery
5%
Injury
5%
Nephropathy
5%
Nursing and Health Professions
Confidence Interval
37%
Prostate Cancer
25%
Man
23%
Adverse Event
22%
Systematic Review
21%
Symptom
18%
Meta Analysis
14%
Procedures
13%
Quality of Life
12%
Arterial Embolization
10%
Patient
10%
Prostate Specific Antigen
10%
Time
10%
Robotics
9%
Gemcitabine
8%
Follow up
8%
Prostatectomy
8%
Data Base
8%
Standard
7%
Transurethral Resection
7%
Chronic Prostatitis
6%
Sexual Dysfunction
6%
Non Muscle Invasive Bladder Cancer
6%
Publication
5%
Prostate Hypertrophy
5%
Neoplasm
5%
Malignant Neoplasm
5%
Placebo
5%
Device Material
5%
Inpatient
5%
Diagnosis
5%
Analysis
5%